The German Cancer Research Center is a member of the Helmholtz Association of National Research Centers. Currently there have seven research programs. Towards the goal of accelerating the translation of research findings into clinical treatments, the cancer research excellence of the DKFZ and the treatment expertise of the University Hospitals Heidelberg and Mannheim have been combined by forming a comprehensive cancer center, the National Center for Tumor Diseases (NCT) Heidelberg together with German Cancer Aid (KH) and other partners (Thorax Clinic Heidelberg, Department of Orthopaedic Surgery).
The role in the project is the genome-wide analysis of ZFN and TALEN associated off-target activity using nr/LAM-PCR and non-PCR based insertion site analysis techniques and bioinformatic analysis tools; quantification of on-target genome modification by ZFN/TALEN. The Key personnel is Christof von Kalle, MD, PhD: Director of the National Centre for Tumor Diseases (NCT) and head of the department “Translational Oncology” at the German Cancer Research Centre (DKFZ), Heidelberg.